ENTPD1

Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®

Retrieved on: 
Monday, August 29, 2022
Nature, Lung cancer, Neoplasm, ENTPD1, Patient, Treatment, University, Technology, RNA, Cancer, Survival, Research, Gene, OS, RFS, Protein, Cell membrane, Solution, High, Adenosine, Randomized controlled trial, University of Alabama, HR, Society, Overalls, GM, Hope, GameChanger, VITAL, Colorectal cancer, OU School of Community Medicine, Skin, Maintenance, Diagnosis, CD39, DNA, HRP, Obstetrics, CSO, GLOBE, Epitope, Immune system, Immunotherapy, Biomarker, The Lancet, Clinical trial, Ovarian cancer, Gynaecology, Melanoma, American Society of Clinical Oncology, BRCA, Phase 1, Pharmaceutical industry, Medical imaging, Vaccine, DALLAS

High ENTPD1 was associated with improved RFS and OS following Vigil maintenance treatment in frontline ovarian cancer patients.

Key Points: 
  • High ENTPD1 was associated with improved RFS and OS following Vigil maintenance treatment in frontline ovarian cancer patients.
  • ENTPD1 has been identified as playing a role in numerous other solid tumor indications, including melanoma, lung cancer and colorectal cancer.
  • The findings published today further underscore the clinical utility of biomarker approaches to predict survival differences across BRCAwt and HRP positive ovarian cancer patients treated with Vigil.
  • Every year, an estimated 22,000 patients are diagnosed with ovarian cancer in the U.S. and 14,000 patients die.

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021

Retrieved on: 
Thursday, August 5, 2021
Company, GlaxoSmithKline, Stomach, NT5E, U.S. Securities and Exchange Commission, Forward-looking statement, Asco, Large-cell lung carcinoma, American Society of Clinical Oncology, Novartis, Pancreatic cancer, Hepatocellular carcinoma, Annual report, Roche, Security (finance), Private Securities Litigation Reform Act, Bevacizumab, IND, ENTPD1, GSK, Patient, PVRIG, COVID-19, Drug discovery, Interleukin 27, Tumor microenvironment, Society, Non-small-cell lung carcinoma, Phase 1, Risk, HCC, CCR8 (gene), Renal cell carcinoma, Research, R, RCC, Annual general meeting, G&A, Corporation, GLOBE, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2021, and provided an update on anticipated corporate milestones.

Key Points: 
  • The second quarter marked a major milestone for Surface, with SRF388 monotherapy eliciting the first-ever clinical response from a therapeutic targeting the IL-27 pathway.
  • On June 4, 2021, Surface presented preliminary data from the ongoing Phase 1 study of SRF388, an anti-IL-27 antibody, at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
  • R&D expenses included $0.9 million in stock-based compensation expense for the second quarter ended June30, 2021.
  • G&A expenses included $1.4 million in stock-based compensation expense for the second quarter ended June30, 2021.

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Retrieved on: 
Thursday, July 15, 2021
Clinical medicine, Medical specialties, Medicine, Clusters of differentiation, Immunology, NT5E, Immune system, Monoclonal antibody, Immunotherapy, Tumor microenvironment, Cancer immunotherapy, ENTPD1

The Company will continue to advance the development of mupadolimab in oncology, where it is currently being studied in a Phase 1/1b clinical trial.

Key Points: 
  • The Company will continue to advance the development of mupadolimab in oncology, where it is currently being studied in a Phase 1/1b clinical trial.
  • Mupadolimab (formerly CPI-006) is a humanized anti-CD73 antibody that binds to various immune cells including most B cells.
  • Binding to CD73 inhibits production of immunosuppressive adenosine in the tumor microenvironment, similar to other recently described anti-CD73 antibodies.
  • In addition, Corvus has published results from the initial cohorts of its Phase 1 COVID-19 study and pre-clinical data characterizing the novel immunotherapy approach with mupadolimab online at medRxiv.org.

I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, March 11, 2021
Clusters of differentiation, Branches of biology, Medical specialties, NT5E, Tumor microenvironment, Programmed cell death protein 1, Clinical medicine, Stromal cell, ENTPD1

Internally discovered by I-Mab, uliledlimab is a novel and highly differentiated antibody that targets the CD73 to modulate adenosine enriched cancer microenvironment.

Key Points: 
  • Internally discovered by I-Mab, uliledlimab is a novel and highly differentiated antibody that targets the CD73 to modulate adenosine enriched cancer microenvironment.
  • Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.
  • Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-1 and PD-(L)1 antibodies.
  • Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

Surface Oncology to Present Preclinical Data for Lead Product Programs at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Immunology, ENTPD1, Antibody, Branches of biology, Biology

The posters include preclinical data from Surface Oncologys two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27).

Key Points: 
  • The posters include preclinical data from Surface Oncologys two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27).
  • Summaries are provided below; full posters will be placed on Surface Oncologys website following the presentations.
  • Details of the AACR presentations are as follows:
    SRF617 is a potent inhibitor of CD39 enzymatic activity both in vitro and in vivo.
  • In addition, any forward-looking statements contained in this press release are based on assumptions that Surface Oncology believes to be reasonable as of this date.

Surface Oncology to Participate in Upcoming March Investor Conferences

Retrieved on: 
Wednesday, February 24, 2021
Pharmaceutical companies, Companies, Life sciences, Cancer immunotherapy, ENTPD1, Tumor microenvironment, Novartis

H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021, presentation recording will be available to investors during the course of the conference.

Key Points: 
  • H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021, presentation recording will be available to investors during the course of the conference.
  • The presentations will focus on Surfaces lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surfaces emerging pre-clinical program, SRF114 (targeting CCR8).
  • Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment.
  • In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical).

I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.

Retrieved on: 
Friday, February 5, 2021
Clusters of differentiation, Branches of biology, Medical specialties, NT5E, Biology, Tumor microenvironment, Adenosine monophosphate, Antibody, ENTPD1

Uliledlimab is a humanized CD73 antibody and works effectively on modulating tumor microenvironment through inhibition of the adenosine pathway.

Key Points: 
  • Uliledlimab is a humanized CD73 antibody and works effectively on modulating tumor microenvironment through inhibition of the adenosine pathway.
  • Uliledlimab is shown to strongly suppress tumor growth especially when combined with a PD-(L)1 inhibitor in pre-clinical studies.
  • As a differentiated CD73 antibody, uliledlimab interacts with a unique epitope to function through a novel intra-dimer binding mode, thus enabling differentiated and favorable functional properties.
  • Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.

Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients

Retrieved on: 
Wednesday, May 20, 2020
Medicine, Medical specialties, Clinical medicine, Bayer AG, Kenilworth, New Jersey, Merck & Co., Schering-Plough, ENTPD1, Merck, Immune system, Pembrolizumab, Adenosine

SRF617 inhibits CD39, an enzyme critical both to the breakdown of adenosine triphosphate (ATP) and the production of adenosine.

Key Points: 
  • SRF617 inhibits CD39, an enzyme critical both to the breakdown of adenosine triphosphate (ATP) and the production of adenosine.
  • A substantial body of research supports a role for CD39 in allowing cancer to evade immune responses.
  • The combination of SRF617 and KEYTRUDA has the potential to overcome this barrier to immune system activation and promote anti-tumor immunity.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials

Retrieved on: 
Monday, January 27, 2020
Medical specialties, Medicine, Adenosine, Nucleosides, Purines, Vasodilators, Organ systems, ENTPD1

I am extremely grateful for the efforts of our employees and their tremendous contributions to Surfaces rapid progress and strong culture.

Key Points: 
  • I am extremely grateful for the efforts of our employees and their tremendous contributions to Surfaces rapid progress and strong culture.
  • The active INDs for both SRF617 and SRF388 enable Surface Oncology to initiate phase 1 clinical trials for each product candidate.
  • The Company anticipates providing initial clinical updates for both SRF617 and SRF388 by the end of 2020.
  • Due to this dual mechanism, Surface Oncology believes CD39 is the most promising therapeutic target on the adenosine axis, a notable immunosuppressive pathway.

Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day

Retrieved on: 
Monday, November 18, 2019
Cancer immunotherapy, ENTPD1, Tumor microenvironment, Medicine, Medical specialties, Clinical medicine

Due to this dual mechanism, Surface Oncology believes CD39 is the most promising therapeutic target on the adenosine axis, a notable immunosuppressive pathway.

Key Points: 
  • Due to this dual mechanism, Surface Oncology believes CD39 is the most promising therapeutic target on the adenosine axis, a notable immunosuppressive pathway.
  • Surface Oncology also anticipates the filing of an IND for SRF388 before the end of 2019, with the subsequent initiation of a phase 1/1b clinical study in early 2020.
  • Surface Oncologys preclinical data demonstrates that SRF813 increases NK and T cell activity, has strong, differentiated preclinical efficacy and promotes immunological memory.
  • Surface Oncologyis an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD112R.